Similarly, the POLARIS-01 study showed poor clinical outcomes of toripalimab, a humanized antibody targeting PD1, among 22 Chinese patients with mucosal melanoma, with an ORR of 0%, a median OS of 10.3 months, and a median PFS of 1.9 months [54]. Here, PDCD1 is linked to mucosal melanoma.